Oxford Asset Management’s Denali Therapeutics DNLI Stock Holding History

Oxford Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-22,231	Closed	-$323K	–	567
2025 Q3	$323K	Buy	+22,231	New	+$319K	0.11%	343
2025 Q2	–	Sell	-14,249	Closed	-$194K	–	593
2025 Q1	$194K	Buy	+14,249	New	+$273K	0.09%	361
2019 Q2	–	Sell	-16,384	Closed	-$380K	–	1760
2019 Q1	$380K	Buy	+16,384	New	+$343K	0.01%	1339
2018 Q1	–	Sell	-122,995	Closed	-$1.85M	–	1674
2017 Q4	$1.85M	Buy	+122,995	New	+$2.21M	0.04%	618

Other funds holding DNLI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Oxford Asset Management's DNLI Position: Q4 2025 in Review

Oxford Asset Management sold out of Denali Therapeutics (DNLI) in Q4 2025, closing a stake of 22,231 shares — an estimated $323K sold.

Oxford Asset Management first reported a position in DNLI in Q4 2017 and held it in 4 quarters. The position peaked at $1.85M in Q4 2017. 250 funds tracked by Wall St. Rank hold DNLI as of Q4 2025.

Oxford Asset Management reported no remaining Denali Therapeutics position as of Q4 2025 after selling out during the quarter.
Oxford Asset Management sold 22,231 Denali Therapeutics shares in Q4 2025, an estimated $323K.
Oxford Asset Management first reported a position in Denali Therapeutics in Q4 2017 and held it in 4 quarters.
Oxford Asset Management's Denali Therapeutics position peaked at $1.85M in Q4 2017.
250 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2025.

Based on Oxford Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.